THERAPEUTICS
Review: Insufficient evidence on Huperzine A for Alzheimers
| The first 150 words of the full text of this article appear below. |
How effective and safe is Huperzine A for Alzheimers disease?
Changes in cognitive function (eg, from scores on Mini Mental State Examination (MMSE), Hasegawa Dementia Scale (HDS), or ADAS-Cog), changes to global clinical assessment (eg, from scores on Clinical Dementia Rating (CDR) or Clinician Interview-Based Impression (CIBIC-Plus)), all cause mortality, adverse events.
Design: Systematic review with meta-analysis.
Data sources: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, CBM, AMED and relevant websites were searched in February 2006. Relevant journals and reference lists of studies were hand searched; unpublished material was identified by contacting experts in the field.
Study selection and analysis:
All RCTs of Huperzine A in adults with Alzheimers disease (AD) of any severity were included. Participants had to be diagnosed with AD using standard criteria (ICD-9 or -10, DSM III, III-R or IV, or National Institute of Neurological and Communicative Disorders and Stroke - Alzheimers
Clinician-Scientist, Rotman Research Institute, Baycrest and Assistant Professor, University of Toronto Department of Medicine, Neurology Division and Department of Psychiatry, Geriatric Psychiatry Division, Toronto, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
